NEW YORK, March 21 - Nanogen plans to launch 10 new analyte specific reagents in 2002, according to a company official.
Speaking to investors at the sparsely attended Banc of America Genomics & Diagnostics conference here on Wednesday, Randy White, Nanogen's CEO, said the firm plans to introduce an ASR for cystic fibrosis in the second quarter, an HIV genotype in the second half of the year, and one on-chip amplified test by the end of the year.
The company that day had released its first ASR, a product designed to detect Factor V Leiden, a gene mutation linked to cardiovascular disease and the pathology of thrombosis.
White would not offer details about the remaining six products but said the firm will disclose them in a conference call at the end of April.
"The introduction of the ASR is an important step in the company's strategy to build its consumable revenue base," Howard Birndorf, executive chairman and co-founder of Nanogen, said in a statement on Wednesday.
The Factor V Leiden ASR helps detect a specific polymorphism to determine if the gene is present in a blood sample.